FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Guide on Gene Therapy Observational Studies

Federal Register notice: FDA makes available a final guidance entitled Long Term Follow-Up After Administration of Human Gene Therapy Products.

FDA General

FDA Warning on Nicotine Toothpicks

FDA issues a Warning Letter to Smart Toothpicks (Tempe, AZ) after the agency determined that its dissolvable tobacco products, Peppermint Ice Nicotine...

Federal Register

Guide on Creutzfeldt-Jakob Disease Risk Reductions

Federal Register notice: FDA makes available a draft guidance on recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob Dise...

Medical Devices

Olympus Enhanced Reprocessing Duodenoscope Cleared

FDA clears an Olympus 510(k) for the TJF-Q190V duodenoscope with a sterile, disposable distal endcap for enhanced reprocessing.

FDA General

Hahns 1st Address Targets Data Modernization as Priority

In his first address to FDA employees, FDA commissioner Stephen Hahn says unleashing the power of data will be a key objective while he is at the agen...

Medical Devices

Medtronic Cybersecurity Patches for Cardiac Devices

FDA says that Medtronic has released the first round of software updates to address some cybersecurity vulnerabilities identified in wireless telemetr...

Human Drugs

FDA Approves Peanut Allergy Drug

FDA approves Aimmune Therapeutics Palforzia [peanut (Arachis hypogaea) allergen powder-dnfp] for treating peanut allergies.

Human Drugs

FDA Seeks Bacitracin for Injection Market Withdrawal

FDA requests that all bacitracin for injection manufacturers voluntarily withdraw their product from the market because the benefits no longer outweig...

Human Drugs

FDA Approves Teva's Ajovy Autoinjector

FDA approves a Teva Pharmaceuticals an autoinjector device for its Ajovy (fremanezumab-vfrm) injection for preventing migraine in adults.

Human Drugs

Aprea Therapeutics Breakthrough for Azacitidine

FDA grants Aprea Therapeutics a breakthrough therapy designation for APR-246 in combination with azacitidine for treating myelodysplastic syndromes.